ERBB2 and breast carcinoma: (13) again turned their attention to the adjuvant efficacy of T-DM1, they found that adjuvant T-DM1 treatment reduced the risk of recurrence and death in HER2-positive early-stage breast cancer patients with residual invasive breast cancer (NCT01772472).